{
    "clinical_study": {
        "@rank": "21588", 
        "arm_group": {
            "arm_group_label": "Macrolane VRF20", 
            "arm_group_type": "Other", 
            "description": "All subjects will receive treatment with Macrolane VRF20 to correct pectus excvatum deformity."
        }, 
        "brief_summary": {
            "textblock": "This is a prospective, open, non-comparative and baseline-controlled study to evaluate\n      efficacy and safety of Macrolane VRF20 treatment in 40 subjects with pectus excavatum\n      deformity.\n\n      Each subject participating in the study will be treated with approximately 50-150 ml of\n      Macrolane VRF20. The amount of study product used will be individually determined in order\n      to achieve an optimal correction of the deformity in each subject."
        }, 
        "brief_title": "Treatment of Pectus Excavatum Deformity Using Macrolane Filler", 
        "condition": "Pectus Excavatum Deformity", 
        "condition_browse": {
            "mesh_term": [
                "Congenital Abnormalities", 
                "Funnel Chest"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Give verbal and written informed consent to participate in the study.\n\n          2. Be a healthy male of 18 years or more.\n\n          3. Have a pectus excavatum deformity without functional problems; score 4 in items 10,\n             11 and 12 of the PEEQ, indicating there is no functional impairment due to the pectus\n             excavatum deformation.\n\n          4. Present normal cardiac function as assessed by ECG and echocardiogram.\n\n          5. Present normal pulmonary function as assessed by pulmonary function test.\n\n          6. Present a chest X-ray taken within 12 months prior to the baseline visit, without\n             clinically significant defects to heart, lungs, skeleton, ribs, sternum or spinal\n             cord except for the pectus excavatum defect, in the opinion of the Investigator.\n\n          7. Have the ability to understand and comply with the requirements of the study.\n\n        Exclusion Criteria:\n\n          1. Score 1, 2 or 3 in either of items 10, 11 and 12 of the PEEQ, indicative of\n             functional problems due to the pectus excavatum deformity.\n\n          2. Previous treatment for the same indication.\n\n          3. Known or suspected hypersensitivity to hyaluronic acid based products.\n\n          4. BMI < 20.\n\n          5. A history of severe allergies manifested by a history of anaphylaxis, or a history or\n             presence of multiple severe allergies (as judged by the Investigator).\n\n          6. Known allergy to any anesthesia planned during the study.\n\n          7. Presence of autoimmune disease or other chronic disease that in the opinion of the\n             Investigator may interfere with the outcome of the study.\n\n          8. Subjects with bleeding disorders or subjects who are taking thrombolytics or\n             anticoagulants, or have taken inhibitors of platelet aggregation, including\n             non-steroidal anti-inflammatory agents and acetylsalicylic acid, two weeks before\n             treatment.\n\n          9. Subjects on immunomodulatory therapy (suppressive or stimulatory).\n\n         10. Subjects with contraindications for MRI, such as presence of pacemaker, clips or\n             splinter, or tendency for claustrophobia.\n\n         11. Any condition which in the opinion of the Investigator makes the subject unsuitable\n             for inclusion (e.g., subjects not likely to participate for the duration of the\n             study).\n\n         12. Use of any investigational drugs or devices within 30 days prior to baseline.\n\n         13. Subjects who are study site staff for this study, or close relatives of the study\n             site staff, as well as subjects who are employed by the Sponsor company, or close\n             relatives of employees at the Sponsor company."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01750112", 
            "org_study_id": "31GC1201"
        }, 
        "intervention": {
            "arm_group_label": "Macrolane VRF20", 
            "intervention_name": "Injection treatment with Macrolane VRF20", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pectus excavatum", 
            "funnel chest", 
            "sunken chest"
        ], 
        "lastchanged_date": "November 8, 2013", 
        "location": [
            {
                "contact": {
                    "email": "raphaelsinna@gmail.com", 
                    "last_name": "Raphael Sinna, Md, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Amiens", 
                        "country": "France"
                    }, 
                    "name": "Raphael Sinna"
                }, 
                "investigator": [
                    {
                        "last_name": "Raphael Sinna, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Pascal Berna, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "mk@drkloeppel.com", 
                    "last_name": "Mrkus Kl\u00f6ppel, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Munchen", 
                        "country": "Germany"
                    }, 
                    "name": "Markus Kl\u00f6ppel"
                }, 
                "investigator": {
                    "last_name": "Markus Kl\u00f6ppel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "per.heden@ak.se", 
                    "last_name": "Per Heden, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden"
                    }, 
                    "name": "Per Heden"
                }, 
                "investigator": [
                    {
                        "last_name": "Per Heden, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Per Bergenz, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Germany", 
                "Sweden"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Non Comparative Multicenter Prospective Study to Evaluate Efficacy and Safety of Macrolane VRF20 in Treatment of Pectus Excavatum", 
        "overall_official": [
            {
                "affiliation": "Akademikliniken", 
                "last_name": "Per Hed\u00e9n, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University Hospital of Amiens", 
                "last_name": "Raphael Sinna, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "MediCenter M\u00fcnchen-Solln", 
                "last_name": "Markus Kl\u00f6ppel, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Sweden: Medical Products Agency", 
                "Sweden: Regional Ethical Review Board", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: Ethics committee", 
                "Germany: Ethics Commission", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To evaluate improvement from baseline in general self-esteem and emotion at each follow up visit after treatment with Macrolane VRF20, using a modified version of the pectus excavatum evaluation questionnaire (PEEQ) before and after treatment.", 
                "measure": "PEEQ", 
                "safety_issue": "No", 
                "time_frame": "Dec 2015"
            }, 
            {
                "description": "Evaluate subject satisfaction at each visit after treatment.", 
                "measure": "Subject satisfaction", 
                "safety_issue": "No", 
                "time_frame": "Dec 2015"
            }, 
            {
                "description": "Estimate duration of Macrolane VRF20 calculated using MRI images.", 
                "measure": "Duration", 
                "safety_issue": "No", 
                "time_frame": "Dec 2015"
            }, 
            {
                "description": "Assess placement using MRI at 1 and 12 months post treatment.", 
                "measure": "Placement", 
                "safety_issue": "No", 
                "time_frame": "Dec 2015"
            }, 
            {
                "description": "To study safety throughout the study period based on evaluation of reported Adverse Events.", 
                "measure": "Adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "Dec 2015"
            }, 
            {
                "description": "Evaluate recovery time after treatment using subject diary.", 
                "measure": "Downtime", 
                "safety_issue": "Yes", 
                "time_frame": "Dec 2015"
            }, 
            {
                "description": "Evaluate days hospitalized or on sick leave after treatment.", 
                "measure": "Downtime 2", 
                "safety_issue": "Yes", 
                "time_frame": "Dec 2015"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01750112"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Q-Med AB", 
        "sponsors": {
            "collaborator": {
                "agency": "Pharma Consulting Group AB", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Q-Med AB", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}